Filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF), and sargramostim, a recombinant granulocytemacrophage colony-stimulating factor (GM-CSF), have been available in the United ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug.

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

fibroblast growth factor receptor 1 (FGFR1) and colony-stimulating factor-1 receptor (CSF-1R). PD-1/PD-L1 inhibitor Tyvyt was ...

FORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a ...